Objective Current evidence on the effectiveness of SARS-CoV-2 prophylaxis is inconclusive.
We aimed to systematically evaluate published studies on repurposed drugs for the …

Due to the rapid, vast, and emerging global spread of the Coronavirus Disease 2019
(COVID-19) pandemic, many drugs were quickly repurposed in a desperate attempt to …

Background SARS-CoV-2 has caused a worldwide pandemic since December 2019 and the
search for pharmaceutical targets against COVID-19 remains an important challenge. Here …

新型冠状病毒感染疫情对人类健康和全球经济造成重创. 健康相关脆弱人群的免疫功能减退,
导致疫苗的防护效果不足, 并且, 感染新型冠状病毒后重症和死亡风险更高, 而目前尚缺乏足够有 …

Background To investigate whether ivermectin inhibits SARS CoV 2 proliferation in patients
with mild-to-moderate COVID-19 using time to a negative COVID-19 reverse transcription …

Effective follow-up strategies are crucial for managing patients' risks of adverse outcomes
(AOs) and associated costs. Current literature on follow-up strategy design primarily focuses …

Ivermectin is an anti-parasitic agent that has gained attention as a potential COVID-19
therapeutic. It is a compound of the type Avermectin, which is a fermented by-product of …

Ivermectin was popular drug on trial for preventive and therapeutic role in COVID-19.
However, there is disagreement concerning the validity of its clinical efficacy. Hence, we …

This systematic review was performed to determine the population that benefited from
prophylactic ivermectin. Seven databases of health‐related studies were searched for …

Background: The COVID-19 pandemic, resulting in approximately seven million deaths
globally, underscores the urgency for effective treatments. Ivermectin, among several …